FDA rejects China-developed lung cancer drug ivonescimab
The FDA rejected ivonescimab, a closely watched lung-cancer treatment developed in China. The decision creates a regulatory setback for a drug viewed as a symbol of China’s growing role in pharmaceutical innovation.
STOCK PHOTO · PHIL EVENDENThe story
The FDA rejected ivonescimab, according to The New York Times, dealing a setback to a closely watched lung-cancer treatment from China. The drug had attracted attention beyond its clinical use because it came to represent China’s advance in drug development.
Ivonescimab’s significance therefore extends beyond a single treatment decision: its regulatory outcome is being read against the broader expansion of China’s pharmaceutical research and development capabilities. The rejection changes the near-term status of a program that had drawn international scrutiny.
The reporting identifies the FDA and the drug’s Chinese developers as the central parties, but no company, filing rationale, trial result, or revised development timetable is established here. The mechanism for affected businesses would run through approval prospects, future commercialization and the value placed on comparable China-originated drug candidates.
The basis for the rejection, and whether the developers can address the FDA’s concerns, remain open. The next material evidence would be the agency’s detailed decision, any response from the developers, and a subsequent regulatory or clinical milestone.
Our read · Sun, Nov 15
The FDA rejected China-developed ivonescimab, a closely watched lung-cancer treatment seen as a symbol of Chinese drug innovation.
Why. The immediate consequence is a setback for ivonescimab’s approval path, but the commercial and scientific impact cannot be assigned to a listed company without an identified developer or the FDA’s reasoning. The decisive evidence will be the agency’s detailed concerns and the developer’s response, including whether the program can return to the review process.
Both cases
What could change this view: The FDA may provide a remediable explanation, allowing the drug to resume development or review without a lasting read-through to other Chinese drug programs.
Who reported it · 2
Keep reading
Latest on the Wire
Trump threatens overseas AI data-centre ban for US firmsBitcoin drops below $59,000 as cash rush revives summer-low testGreer says US chip curbs will close China export-control loopholesBlackRock bitcoin ETF posts $541.1 million outflow as tech sell-off spreadsPoland says Russian missiles and drone crashed during Ukraine assaultContinue on the Wire →Latest on the Wire
Anthropic debut fails to halt technology-led slide in US stocksUS MATCH Act puts ASML at center of China chip export disputeGerman producer prices jump 8.1% in October as industrial inflation acceleratesChina seeks protections to restart US private-equity investmentsContinue on the Wire →Top this week
Nvidia chair rules out Huang return as CEO after 75% sales outlookAnthropic Said to Guide IPO Pricing Above Market RangeNvidia interim CEO Colette Kress faces first earnings test after HuangAnthropic IPO could become the largest in US history on ThursdayBitcoin nears $64,000 as Anthropic IPO lifts Nasdaq futures nearly 2%About this report
Reported by NYT Business as F.D.A. Rejects Closely Watched Lung Cancer Drug From China
, . Who answers for this
2 reports from 2 publishers in this record. Closes are licensed end-of-day data from Databento; the move after a story is its first close against the close before it. How this is decided →
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →